SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition.

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Pancreatic cancer has a poor 5-year survival rate, necessitating novel therapeutic strategies.
• Transforming growth factor beta (TGFβ) is implicated in pancreatic cancer's desmoplasia, immune suppression, and chemoresistance.
• Previous TGFβ-targeted therapies in unselected patients have failed FDA approval, suggesting a need for patient stratification.

Purpose of the Study:

• To investigate if SMAD4 mutational status can stratify pancreatic cancer patients for TGFβ inhibitor therapy.
• To explore the role of SMAD4 deficiency in pancreatic cancer progression and response to TGFβ blockade.

Main Methods:

• Analysis of SMAD4 expression in human pancreatic tumors.
• Utilizing SMAD4-deficient genetically engineered and orthotopic mouse models.
• Treatment of SMAD4-deficient tumors with a blocking TGFβ antibody.

Main Results:

• SMAD4 mutation or loss correlated with worse disease-free survival in human pancreatic tumors.
• SMAD4-deficient mouse models showed reduced survival, increased metastasis, and altered tumor microenvironments.
• TGFβ antibody treatment significantly reduced tumor weight and improved survival in SMAD4-deficient mice.

Conclusions:

• Genomic stratification based on TGFβ axis alterations, like SMAD4 mutations, can identify pancreatic cancer patients likely to benefit from TGFβ inhibitors.
• Targeting TGFβ in SMAD4-deficient pancreatic cancers offers a potential therapeutic strategy to improve standard and immune therapies.